Hot Features
Premium
Register for real-time alerts, custom portfolio, and market movers
Biotechnology Industry has been of the fastest growing for past few years as the market has seen fast paced developments in terms of research and development, government regulations and new avenues. Due to innovations government support and significant increase in the public and private investment the industry has growth at a CAGR of 7% since 2009.
Amgen Inc (NASDAQ:AMGN): The company operates in the field of Biotechnology Medicines engaging in development, manufacturing and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. In the latest reported results for full year 2012, the company posted total revenues of $17,265 million an increase of 11% from previous year and a 9% increase in the sales across the portfolio and an adjusted EPS grew to $6.51 per share. The company had a profitability margin of 25.17% and operating margin of 34.66%. For its long term growth strategy the company has focussed on manufacturing of high quality of biologics. The company is poised for high growth in International Markets.
The company recently announced dividends of $0.47 per share for the second quarter 2013 highest ever. The stock is presently trading around $93 with expected Forward P/E ratio of 11.29 with Return on Equity of 22.82%.
Baxter International Inc.(NYSE:BAX)- The company through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company operates in two segments, BioScience and Medical Products. In the recently reported results for full year 2012, the company reported net income of $2.3 billion an increase of 2%from previous year or $3.88 per diluted share. The company has increased its investment in research and development too $1.2 billion.
BAX has recently agreed to acquired the investigational hemophilia compound OBI-1 and related assets from Inspiration BioPharmaceuticals, Inc. as well as certain other OBI-1 related assets, including manufacturing operations, from Ipsen Pharma S.A.S. in conjunction with Inspiration’s ongoing bankruptcy proceedings. The transaction is subject to bankruptcy court and regulatory approvals for an upfront payment of $50 million. The company has submitted a biologics license application supplement to the U.S. FDA for the approval of prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, in patients with hemophilia A or B and inhibitors.
The stock is trading around $69 with a P/E ratio of 16.72 and EPS of 4.19
Celgene Corporation (NASDAQ:CELG)- Celgene Corporation, a biopharmaceutical company, engaged in the discovery, development, and commercialization of various therapies to treat cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. In it’s recently reported financial results for year 2012, the company posted total net sales of around $5.4 billion up by 14% from last year, net revenue of $5.5 billion, adjusted diluted EPS of $4.90. The company’s operating margin is 37%. Looking ahead, the company expects total sales of $6 billion for 2013 and plans to reach a target sales of $12 billion net by 2017 with a CAGR of 19%. Recently FDA has approved POMLYST brand therapy for patients with multiple myeloma.
The company has recently entered an accelerated share repurchase agreement worth $600 million as a part of its repurchase program of which approximately $1,450 million are remaining.
The stock is trading around $110 with forward P/E for fiscal year ending 2014 at 16.16. The stocks of the company in last 52 weeks have traded in the range of $58.53- $110.80 a change of 46.55%
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)- The Company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company sells its products primarily in the United States, Europe, and the Asia Pacific. In its recently reported financial results for the full year 2012, the company reported net product sales of $1,134 billion an increase of 45% from the previous year, net income of $254.8 million or $1.28 per share. For 2013, the company expects its net product sales to be in the range of $1.490-$1.505 billion and future EPS to be in the range of $2.82-$2.92.
The company has an ongoing share repurchase program for $400 million. Recently TRC corporation has made Mini tender offer for purchasing Alexion’s shares the offer has been made to purchase up to 1.5 million shares.
The stock is presently trading around $92with ROE of 16.41%. P/E ratio is 72.63 and EPS of 1.28. In last 52 weeks, shares of the company have traded within the range of $119.539-$81.278.
Gilead Sciences Inc. (NASDAQ:GILD)- Gilead is a biopharmaceutical company engaged in discovering, developing, and commercializing human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Its products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; and Viread and Hepsera products for the treatment of liver disease. In its recently announced financial results the company reported revenues of $9.70 billion, increase of 16%, adjusted net income of $2.59 billion with diluted EPS of $1.64. The company recently completed its aquistion of YM Bio Sciences for approximately $501 million.
The stock is currently trading around $45 with P/E of 27.49. In last 52 weeks, the stock has traded in the range of $22.40-$45.58
In most multiple bank account bags in the entire width in the
dashboard, there exists heavy work leather that come with all
bags and that is screwed for the dashboard.
Through this process, the team confirmed the importance of
research based on optimization of content and the accessibility in search engines to achieve business goals.
In general terms, the website content is understood as the content that is being displayed over the site pages.
End users also have the option to only search for
Google+ Local businesses. Just get into a rhythm of submitting like 10 links ever day if you can.
Try different types of ads; some with flashy graphics and maybe a video promoting your product and
some with a simpler text based ad.